Is IDO1 an adequate target for treatment in glioblastoma?
Por:
Siancas, CAM, Gonzalez, AH, Domenech, M, Esteve-Codina, A, Arpi, O, Alameda, F, Pineda, E, Chekhun, S, Paradis, AL, Del Barco, S, De la Iglesia, N, Rubio, OG, Mesia, C, Mallo, M, Esteve, A, Carrato, C, Balana, C and Martinez-Garcia, M
Publicada:
1 jun 2022
Resumen:
Filiaciones:
Hosp Germans Trias i Pujol, Badalona, Spain.
Inst Catala Oncol Badalona, Badalona, Spain.
Inst Invest Germans Trias i Pujol IGTP, Appl Res Grp Oncol, B ARGO Grp, Barcelona, Spain.
Inst Invest Germans Trias i Pujol IGTP, Badalona, Spain.
Ctr Genom Regulat, CNAG, Barcelona, Spain.
Hosp Mar, IMIM Hosp Mar Res Inst, Canc Res Program, Med Oncol Dept, Barcelona, Spain.
Inst Hosp Mar Invest Med IMIM, Pathol Dept, Neuropathol Unit, Hosp Mar, Barcelona, Spain.
Hosp Clin Barcelona, Med Oncol Serv, Barcelona, Spain.
Hosp Univ Germans Trias i Pujol, Barcelona, Spain.
Germans Trias i Pujol Hosp, Badalona, Spain.
Inst Catal Oncol Girona, Med Oncol Serv, Girona, Spain.
Germasn Trias i Pujol Hosp, IrsiCaixa ADIS Res Inst, Badalona, Spain.
Hosp Santa Creu & Sant Pau, Barcelona, Spain.
Inst Recerca Leucemia Josep Carreras, Badalon, Spain.
Germans Trias i Pujol, Canc Stat Dept, Catalan Inst Oncol Hosp, Badalona, Spain.
Hosp Germans Trias i Pujol, Barcelona, Spain.
Hosp Mar, Med Oncol Serv, Barcelona, Spain.
|